GUTS insider buying & filings

← All candidates

GUTSFRACTYL HEALTH, INC.

NasdaqGM · Healthcare · $125.76M

$0.5760

+1.95% today

One insider bought $39.9K in a single day.
Led by Bradley William, director.

Last Form 4 Sep 16 · scanned 42s ago

Price · 1Y · daily● 4 buys◆ 12 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$125.76M

Float

143.3M

90% public

Short % float

Pro

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Director

Bradley William

Bought $39.9K on Sep 14 — 64,516 sh @ $0.6185, held direct, 43% of their stake.

First Form 4 on file

no positions we can measure against the market — the record starts here

Chief Executive Officer

Rajagopalan Harith

Bought $20.0K on Dec 4 — 10,416 sh @ $1.92, held direct, 2.1% of their stake.

0 of 1 position beat the S&P

median -59.3% vs S&P +10.5% same spans

Director

Royan Ajay

Bought $19.6K on Jun 12 — 23,000 sh @ $0.8520, held direct, 56% of their stake.

First Form 4 on file

no positions we can measure against the market — the record starts here

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Sep 16BUYBradley WilliamDirector+43%direct64,516 @ $0.6185$39.9K

Jun 15BUYRoyan AjayDirector+56%direct23,000 @ $0.8520$19.6K

Jun 9BUYSmith Weber LaraChief Financial Officer+100%direct20,000 @ $0.6854$13.7K

Dec 8BUYRajagopalan HarithChief Executive Officer+2.1%direct10,416 @ $1.92$20.0K

Context

Wall St

$5.24 avg target

+809.7% vs today · 5 analysts

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

1 of 3 quarters beat

Q4 '25−$0.07 act+$0.11

Q3 '25−$0.71 act−$0.39

Q2 '25−$0.57 act−$0.21

Coverage

Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At FundingInsider Monkey · 06-12 Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit TurnaroundSimply Wall St. · 05-16 A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net IncomeSimply Wall St. · 05-14 Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ...GuruFocus.com · 05-13

The file stays open

17 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Bradley William

Rajagopalan Harith

Royan Ajay

17 filings on record.The next one will be too.

17 filings on record.
The next one will be too.